LYRA News and Press, Lyra Therapeutics Inc. From 11/09/21

Lyra Therapeutics, Inc. (LYRA) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Stephanie Marks - Argot Partners Maria Palasis - President and CEO Jason Cavalier - CFO Robert Kern - Chief Medical Officer Corinne Noyes - SVP-Commercial Strategy & Market ...

Lyra Therapeutics (NASDAQ:LYRA): Q3 GAAP EPS of -$0.85 misses by $0.12. Revenue of $0.01M misses by $0.24M. Press Release For further details see: Lyra Therapeutics EPS misses by $0.12, misses on revenue

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update - LYR-210 Phase 3 ENLIGHTEN and LYR-220 Phase 2 BEACON studies on track to initiate around EOY - - New LYR-210 Phase 2 LANTERN 6-month follow up data and LYR-210 PK study presented a...

Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9 PR Newswire WATERTOWN, Mass. , Nov. 2, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ ...

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society Approximately 50% of treated CRS patients experienced durable symptom impro...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis Patients Company to Initiate Phase 3 ENLIGHTEN Program around YE’21...

WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passage...

WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passage...